Sulfonylurea
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Sulfonylurea
Sulfonylurea drugs represent a cornerstone in the management of type 2 diabetes mellitus by stimulating insulin secretion from pancreatic beta cells. These agents bind to the SUR1 subunit of the ATP-sensitive potassium channel (KATP) on beta cells, leading to channel closure, membrane depolarization, and calcium influx, which in turn triggers insulin exocytosis. The primary approved indication for this class is type 2 diabetes, with some combination products also addressing related metabolic dysregulation. The originator drug for this class was DIABETA (glyburide), first approved in 1984 by Sanofi, marking a significant advancement in oral antidiabetic therapy.
While the core mechanism remains consistent, the evolution of sulfonylureas has focused on improving pharmacokinetic profiles, reducing side effects, and enhancing patient convenience. Newer generations aimed for greater potency and longer duration of action, allowing for less frequent dosing. The development also saw the introduction of combination therapies, pairing sulfonylureas with other antidiabetic agents like metformin to achieve better glycemic control through complementary mechanisms.
The future trajectory for sulfonylureas is largely shaped by the emergence of newer antidiabetic classes with distinct mechanisms and potentially more favorable safety profiles, particularly regarding hypoglycemia and weight gain. However, their established efficacy, low cost, and availability as generics ensure their continued relevance, especially in resource-limited settings and for patients refractory to or unable to tolerate newer agents. The focus is shifting towards optimizing their use within current treatment paradigms rather than novel development.
8 FDA-approved Sulfonylurea drugs, including DIABETA, with 46 active Phase 3 trials. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Sulfonylurea Drugs
8 totalSulfonylurea drugs have a well-established history in diabetes management, originating with DIABETA (glyburide) by Sanofi in 1984. This first-generation agent paved the way for subsequent sulfonylureas, including second-generation drugs like glipizide and glyburide, and later, glimepiride. These advancements primarily focused on enhancing potency, extending duration of action, and refining pharmacokinetic profiles to allow for once-daily dosing and potentially reduce the risk of hypoglycemia compared to earlier agents. The evolution aimed to provide more predictable glycemic control and improve patient adherence. Individual sulfonylurea drugs exhibit subtle but clinically relevant differences. Glyburide, for instance, has a longer half-life and is a more potent stimulator of insulin release, which can increase the risk of hypoglycemia, especially in patients with renal impairment. Glipizide has a shorter half-life and is generally considered to have a lower risk profile in this regard. Glimepiride offers a balance, with a long duration of action and a potentially lower risk of hypoglycemia compared to glyburide. Combination products, such as those pairing glyburide with metformin or glimepiride with pioglitazone, offer convenience and synergistic effects by targeting different pathophysiological aspects of type 2 diabetes. Today, sulfonylureas are typically positioned as second-line or third-line therapy for type 2 diabetes, often used when metformin alone is insufficient or in patients who cannot tolerate or afford newer agents like GLP-1 receptor agonists or SGLT2 inhibitors. The market is heavily influenced by generic competition, with numerous manufacturers offering affordable versions of glyburide, glipizide, and glimepiride. While originator brands like DIABETA and DUETACT still exist, their market share is largely ceded to generics. Class-wide safety concerns, particularly hypoglycemia and weight gain, and the availability of agents with cardioprotective or renoprotective benefits, have led to a decline in their first-line use.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.